Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul;27(7):787-94.
doi: 10.1038/eye.2013.107. Epub 2013 May 31.

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

K Ghasemi Falavarjani  1 , Q D Nguyen
Affiliations
Review

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

K Ghasemi Falavarjani et al. Eye (Lond). 2013 Jul.

Abstract

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

PubMed Disclaimer

Comment in

References

    1. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet. 2007;370 (9583:204–206. - PubMed
    1. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248 (7:915–930. - PubMed
    1. Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363 (22:2135–2144. - PubMed
    1. Falavarjani KG, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye. 2010;24:717–719. - PubMed
    1. Nazari H, Parvaresh MM, Modarres M, Falavarjani KG. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol. 2010;248:1713–1718. - PubMed

Publication types

MeSH terms

Substances